Double-Blind Study of Miglitol in Japanese With type2 Diabetes
Information source: Sanwa Kagaku Kenkyusho Co., Ltd.
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Type 2 Diabetes Mellitus
Intervention: miglitol (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Sanwa Kagaku Kenkyusho Co., Ltd. Official(s) and/or principal investigator(s):
Clinical study Group, Clinical Development Dept., Study Director, Affiliation: Sanwa Kagaku Kenkyusho Co., Ltd.
Summary
To investigate the efficacy and safety of miglitol in Japanese patients with type 2 diabetes
that is insufficiently controlled diet alone.
Clinical Details
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 20 Years.
Maximum age: 69 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Type2 diabetic patient on Dietary Therapy
- Criteria for postprandial plasma glucose and HbA1c are met
Exclusion Criteria:
- Type1 diabetes
- Patients treated with antidiabetic drugs or Insulin
Locations and Contacts
Ishikawa, Japan
Iwate, Japan
Miyagi, Japan
Yamagata, Japan
Saitama, Japan
Ibaragi, Japan
Gunma, Japan
Chiba, Japan
Tokyo, Japan
Niigata, Japan
Toyama, Japan
Shizuoka, Japan
Aichi, Japan
Mie, Japan
Shiga, Japan
Kyoto, Japan
Osaka, Japan
Hyogo, Japan
Shimane, Japan
Okayama, Japan
Hiroshima, Japan
Yamaguchi, Japan
Fukuoka, Japan
Saga, Japan
Nagasaki, Japan
Oita, Japan
Kumamoto, Japan
Additional Information
Last updated: September 25, 2006
|
